Conditions: Advanced Solid Malignancies Malignant Lymphoma
Keywords: Advanced solid malignancies Malignant lymphoma
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 43
Healthy volunteers: no

Brief summary:
The purpose of this study is to investigate the safety and tolerability of AZD 1208 up to a maximum tolerated dose (MTD) and define the dose(s) for further clinical evaluation when given daily to patients with advanced solid malignancies including malignant lymphoma

Detailed description:
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD1208 in Patients with Advanced Solid Malignancies including Malignant Lymphoma

Arms:
arm 1: None

Interventions: intervention 1: AZD1208
Intervention descriptions: intervention 1: Dose of AZD1208 will be escalated from 120mg to a maximum tolerated dose

Protocol document: